For melanomas with NF1 loss‐of‐function mutations or deletions, studies have shown that NF1 ablation can be linked to decreased sensitivity and resistance to BRAF inhibitors both in vitro and in vivo (Maertens et al., 2013; Whittaker et al., 2013). Here, BRAF is linked to melanoma.